SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that BGI purchased 12 additional Genome Analyzers, expanding their installed base of Illumina’s next-generation sequencing platforms to 29 units. Of the new units, four will be installed at BGI, Shenzhen and eight will be installed at BGI, Hong Kong. This added capacity will help researchers at BGI expedite efforts around key programs such as the 1000 Genomes Project, the Chinese Cancer Genome project, the Tree of Life project, and other initiatives that accelerate BGI’s work in agriculture, human health, and biofuels.
